Which has preferable earnings and valuation, VRAX or FEMY?

Virax Biolabs Group has higher earnings, but lower revenue than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 228.80 -$5.02M N/A N/A Femasys $2.29M 3.02 -$18.63M -$5.40 N/A

Do analysts rate VRAX or MBAI?

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 774.13%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, research analysts clearly believe Virax Biolabs Group is more favorable than Check-Cap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, VRAX or MBAI?

Check-Cap has lower revenue, but higher earnings than Virax Biolabs Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 228.80 -$5.02M N/A N/A Check-Cap N/A N/A $4.14M -$2.01 N/A

Is VRAX or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Check-Cap N/A N/A N/A

Which has better valuation & earnings, VRAX or HSCS?

Virax Biolabs Group has higher revenue and earnings than HeartSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 228.80 -$5.02M N/A N/A HeartSciences N/A N/A -$9.14M -$3.94 N/A

Is VRAX or HSCS more profitable?

Virax Biolabs Group's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A HeartSciences N/A -358.60% -144.82%

Do analysts prefer NXL or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 774.13%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, NXL or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Nexalin Technology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nexalin Technology $300K 25.71 -$8.22M -$0.47 N/A Virax Biolabs Group $10K 228.80 -$5.02M N/A N/A

Do analysts prefer NVNO or VRAX?

Virax Biolabs Group has a consensus target price of $25.00, indicating a potential upside of 774.13%. Given Virax Biolabs Group's higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, NVNO or VRAX?

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$19.33 N/A Virax Biolabs Group $10K 228.80 -$5.02M N/A N/A

Is NVNO or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% Virax Biolabs Group N/A N/A N/A

Virax Biolabs Group (VRAX) Competitors

$2.86 +0.04 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 -0.05 (-1.92%)

As of 07:54 PM Eastern

Compare

VRAX vs. FEMY, MBAI, HSCS, NXL, and NVNO

Should you buy Virax Biolabs Group stock or one of its competitors? Virax Biolabs Group's main competitors and comparable companies include Femasys (FEMY), Check-Cap (MBAI), HeartSciences (HSCS), Nexalin Technology (NXL), and enVVeno Medical (NVNO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Virax Biolabs Group compare to Femasys?

Virax Biolabs Group (NASDAQ:VRAX) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Femasys had 12 more articles in the media than Virax Biolabs Group. MarketBeat recorded 13 mentions for Femasys and 1 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 1.89 beat Femasys' score of 1.10 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Very Positive
Femasys	Positive

Virax Biolabs Group presently has a consensus target price of $25.00, suggesting a potential upside of 774.13%. Femasys has a consensus target price of $56.67, suggesting a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Virax Biolabs Group has higher earnings, but lower revenue than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	228.80	-$5.02M	N/A	N/A
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virax Biolabs Group has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Virax Biolabs Group's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Femasys	-521.97%	-258.08%	-73.72%

Virax Biolabs Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Femasys has a beta of -2.08, indicating that its stock price is 308% less volatile than the broader market.

Summary

Virax Biolabs Group beats Femasys on 8 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Check-Cap?

Virax Biolabs Group (NASDAQ:VRAX) and Check-Cap (NASDAQ:MBAI) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Check-Cap has lower revenue, but higher earnings than Virax Biolabs Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	228.80	-$5.02M	N/A	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.01	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Check-Cap	N/A	N/A	N/A

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 774.13%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, research analysts clearly believe Virax Biolabs Group is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Check-Cap had 4 more articles in the media than Virax Biolabs Group. MarketBeat recorded 5 mentions for Check-Cap and 1 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 1.89 beat Check-Cap's score of 0.34 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Very Positive
Check-Cap	Neutral

Summary

Virax Biolabs Group beats Check-Cap on 8 of the 10 factors compared between the two stocks.

How does Virax Biolabs Group compare to HeartSciences?

Virax Biolabs Group (NASDAQ:VRAX) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.89 beat HeartSciences' score of 0.94 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Overall Sentiment
Virax Biolabs Group	Very Positive
HeartSciences	Positive

Virax Biolabs Group currently has a consensus target price of $25.00, suggesting a potential upside of 774.13%. HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 288.35%. Given Virax Biolabs Group's higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
HeartSciences	N/A	-358.60%	-144.82%

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Virax Biolabs Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than HeartSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	228.80	-$5.02M	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

Summary

Virax Biolabs Group beats HeartSciences on 7 of the 9 factors compared between the two stocks.

How does Virax Biolabs Group compare to Nexalin Technology?

Nexalin Technology (NASDAQ:NXL) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Virax Biolabs Group has lower revenue, but higher earnings than Nexalin Technology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	25.71	-$8.22M	-$0.47	N/A
Virax Biolabs Group	$10K	228.80	-$5.02M	N/A	N/A

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Nexalin Technology had 2 more articles in the media than Virax Biolabs Group. MarketBeat recorded 3 mentions for Nexalin Technology and 1 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 1.89 beat Nexalin Technology's score of -0.04 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Nexalin Technology	Neutral
Virax Biolabs Group	Very Positive

Virax Biolabs Group has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Virax Biolabs Group's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-4,141.94%	-278.24%	-218.42%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 774.13%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nexalin Technology has a beta of 4, indicating that its share price is 300% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Summary

Virax Biolabs Group beats Nexalin Technology on 11 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has a consensus target price of $25.00, indicating a potential upside of 774.13%. Given Virax Biolabs Group's higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Virax Biolabs Group	$10K	228.80	-$5.02M	N/A	N/A

enVVeno Medical has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, enVVeno Medical had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 2 mentions for enVVeno Medical and 1 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 1.89 beat enVVeno Medical's score of 0.43 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Neutral
Virax Biolabs Group	Very Positive

Summary

Virax Biolabs Group beats enVVeno Medical on 9 of the 13 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.25M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	N/A	21.85	211.09	21.74
Price / Sales	228.80	63.14	602.98	92.99
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	0.07	6.10	12.91	6.24
Net Income	-$5.02M	$148.67M	$3.45B	$347.60M
7 Day Performance	-4.03%	1.84%	1.12%	1.07%
1 Month Performance	-23.53%	4.56%	1.79%	1.03%
1 Year Performance	-84.69%	8.67%	67.69%	20.77%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	2.1641 of 5 stars	$2.86 +1.4%	$25.00 +774.1%	-85.0%	$2.25M	$10K	N/A	5	Positive News
FEMY Femasys	3.2912 of 5 stars	$3.01 -1.3%	$106.67 +3,443.7%	-85.1%	$9.21M	$2.29M	N/A	30	Earnings Report Analyst Forecast
MBAI Check-Cap	0.3156 of 5 stars	$1.30 +13.0%	N/A	N/A	$8.89M	N/A	N/A	80	News Coverage High Trading Volume
HSCS HeartSciences	2.654 of 5 stars	$2.28 +9.6%	$8.00 +250.9%	-41.3%	$8.11M	N/A	N/A	10
NXL Nexalin Technology	0.5043 of 5 stars	$0.34 -5.8%	N/A	-58.2%	$7.95M	$300K	N/A	3	Positive News Earnings Report Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. FEMY, MBAI, HSCS, NXL, and NVNO

How does Virax Biolabs Group compare to Femasys?

Summary

How does Virax Biolabs Group compare to Check-Cap?

Summary

How does Virax Biolabs Group compare to HeartSciences?

Summary

How does Virax Biolabs Group compare to Nexalin Technology?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. FEMY, MBAI, HSCS, NXL, and NVNO

How does Virax Biolabs Group compare to Femasys?

Does the media favor VRAX or FEMY?

Do analysts rate VRAX or FEMY?

Which has preferable earnings and valuation, VRAX or FEMY?

Do institutionals and insiders hold more shares of VRAX or FEMY?

Is VRAX or FEMY more profitable?

Which has more volatility & risk, VRAX or FEMY?

Summary

How does Virax Biolabs Group compare to Check-Cap?

Which has stronger earnings & valuation, VRAX or MBAI?

Is VRAX or MBAI more profitable?

Do institutionals & insiders hold more shares of VRAX or MBAI?

Do analysts rate VRAX or MBAI?

Which has more risk and volatility, VRAX or MBAI?

Does the media refer more to VRAX or MBAI?

Summary

How does Virax Biolabs Group compare to HeartSciences?

Does the media refer more to VRAX or HSCS?

Do analysts rate VRAX or HSCS?

Is VRAX or HSCS more profitable?

Do insiders & institutionals hold more shares of VRAX or HSCS?

Which has more volatility and risk, VRAX or HSCS?

Which has better valuation & earnings, VRAX or HSCS?

Summary

How does Virax Biolabs Group compare to Nexalin Technology?

Which has preferable earnings & valuation, NXL or VRAX?

Do insiders and institutionals believe in NXL or VRAX?

Does the media prefer NXL or VRAX?

Is NXL or VRAX more profitable?

Do analysts prefer NXL or VRAX?

Which has more risk and volatility, NXL or VRAX?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Do insiders and institutionals believe in NVNO or VRAX?

Is NVNO or VRAX more profitable?

Do analysts prefer NVNO or VRAX?

Which has preferable earnings & valuation, NVNO or VRAX?

Which has more volatility and risk, NVNO or VRAX?

Does the media favor NVNO or VRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools